1-苄基-4-(4-氨基丁基)哌嗪 | 4487-05-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苄基-4-(4-氨基丁基)哌嗪
• 英文名称: 4-(4-benzyl-piperazin-1-yl)-butylamine
• 英文别名: 4-(4-benzylpiperazin-1-yl)butan-1-amine
• CAS: 4487-05-2
• 化学式: C₁₅H₂₅N₃
• mdl: MFCD09723558
• 分子量: 247.384
• InChiKey: CELVPVTXKMNJMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-苄基-4-(4-氨基丁基)哌嗪 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 0.25h， 生成 4-(4-benzylpiperidin-1-yl)-N-(3,4-dimethoxybenzyl)butan-1-amine
  参考文献：
  名称：

  Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer’s disease

  摘要：

  Development of Multi-Target Directed Ligands (MTDLs) has emerged as a promising approach for targeting complex etiology of Alzheimer's disease (AD). Following this approach, a new series of N'-(4-benzylpiperidin-/piperazin-/benzhydrylpiperazin-1-yl) alkylamine derivatives were designed, synthesized and biologically evaluated as inhibitors of cholinesterases (ChEs), amyloid-beta (A beta) self aggregation and also for their radical scavenging activity. The in vitro studies showed that the majority of synthesized derivatives strongly inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values in the low-nanomolar range, and were clearly more potent than the reference compound donepezil in this regard. Among them, inhibitors 5h and 5k, strongly inhibited AChE, with IC50 value of 6.83 nM and 2.13 nM, respectively, and particularly, compound 5k was found to be highly selective for AChE (similar to 38-fold). Moreover, both kinetic analysis of AChE inhibition and the docking study suggested that 5k binds simultaneously to catalytic active site and peripheral anionic site of AChE. Besides, these compounds also exhibited greater ability to inhibit self-induced A beta(1-42) aggregation at 25 mu M with percentage inhibition from similar to 54% to 89% and specially compound 5k provided highest inhibition (88.81%). Also, the derivatives containing methoxy and hydroxy groups showed potent oxygen radical absorbance capacity (ORAC) ranging from 2.2- to 4.4-fold of the Trolox value. Furthermore, results of ADMET studies suggested that all compounds exhibited appropriate drug like properties. Taken together, these results suggest that 5k might be a promising lead compound for further AD drug development. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.12.057
• 作为产物：
  描述：

  2-(4-(4-benzylpiperazin-1-yl)butyl)isoindoline-1,3-dione 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以100%的产率得到1-苄基-4-(4-氨基丁基)哌嗪
  参考文献：
  名称：

  [EN] RADIOLABELED COMPOUNDS AND METHODS THEREOF
  [FR] COMPOSÉS RADIOMARQUÉS ET LEURS PROCÉDÉS

  摘要：

  本发明涉及放射诊断化合物，制备这些化合物的方法，以及将其用作HA血清素5-HT1A受体的成像剂，用于PET或SPECT，更好地使用PET的方法。还披露了包含放射标记化合物的成像有效量的组合物。本发明还涉及非放射标记化合物，制备这些化合物的方法，以及将其用于治疗各种神经学和/或精神疾病的方法。

  公开号：

  WO2011150183A1

文献信息

• Acrylamide derivatives as antiallergic agents. I. Synthesis and structure-activity relationships of N-((4-substituted 1-piperazinyl)alkyl)-3-(aryl and heteroaryl)acrylamides.
  作者：Yoshinori NISHIKAWA、Tokuhiko SHINDO、Katsumi ISHI、Hideo NAKAMURA、Tatsuya KON、Hitoshi UNO

  DOI：10.1248/cpb.37.100

  日期：——

  A new series of acrylamide derivatives (7-10) were synthesized. Antiallergic activity of these compounds was evaluated and their structure-activity relationships were examined. Compounds 10d, N[4-(4-diphenylmethyl-1-piperazinyl)buthyl]3-(3-pyridyl)acrylamide, showed antiallergic activity equivalent or superior to that of ketotifen in the rat passive cutaneous anaphylaxis (PCA) test by oral administration. Compound 10d, unlike ketotifen, had more potent in vitro 5-lipoxygenase inhibitory activity than caffeic acid, whereas its in vitro antihistamine activity was weaker than that of ketotifen. In addition, its inhibitory activity against histamine release from rat mast cells was approximately two-thirds as potent as that of disodium cromoglycate (DSCG). Compound 10d is a promising agent for treating a variety of allergic diseases.

  一系列新的丙烯酰胺衍生物（7-10）被合成。对这些化合物的抗过敏活性进行了评估，并考察了它们的结构-活性关系。化合物10d，即N[4-(4-二苯甲基-1-哌嗪基)丁基]3-(3-吡啶基)丙烯酰胺，在口服给药的大鼠被动皮肤过敏反应（PCA）测试中显示出与酮替芬相当或更优越的抗过敏活性。与酮替芬不同，10d在体外对5-脂氧合酶的抑制活性比咖啡酸更强，而其体外抗组胺活性则弱于酮替芬。此外，它对大鼠肥大细胞释放组胺的抑制活性约为色甘酸二钠（DSCG）的三分之二。化合物10d是一种有前途的多种过敏性疾病治疗药物。
• RADIOLABELED COMPOUNDS AND METHODS THEREOF
  申请人：Newington Ian Martin

  公开号：US20130064770A1

  公开（公告）日：2013-03-14

  The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.

  本发明涉及放射性诊断化合物、制备这些化合物的方法以及将其用作成像剂的方法，优选地用于PET或SPECT，特别是HA 5-HT1A受体，其中包括成像有效量的放射性标记化合物的组合物。本发明还涉及非放射性标记化合物、制备这些化合物的方法以及将其用于治疗各种神经和/或精神障碍的方法。
• NISHIKAWA, YOSHINORI;SHINDO, TOKUHIKO;ISHII, KATSUMI;NAKAMURA, HIDEO;KON,+, CHEM. AND PHARM. BULL., 37,(1989) N, C. 100-105
  作者：NISHIKAWA, YOSHINORI、SHINDO, TOKUHIKO、ISHII, KATSUMI、NAKAMURA, HIDEO、KON,+

  DOI：——

  日期：——
• STACK, GARY P.;ABOU-GHARBIA, MAGID A.;PODLESNY, EDWARD J.
  作者：STACK, GARY P.、ABOU-GHARBIA, MAGID A.、PODLESNY, EDWARD J.

  DOI：——

  日期：——
• [EN] RADIOLABELED COMPOUNDS AND METHODS THEREOF<br/>[FR] COMPOSÉS RADIOMARQUÉS ET LEURS PROCÉDÉS
  申请人：GE HEALTHCARE LTD

  公开号：WO2011150183A1

  公开（公告）日：2011-12-01

  The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.

  本发明涉及放射诊断化合物，制备这些化合物的方法，以及将其用作HA血清素5-HT1A受体的成像剂，用于PET或SPECT，更好地使用PET的方法。还披露了包含放射标记化合物的成像有效量的组合物。本发明还涉及非放射标记化合物，制备这些化合物的方法，以及将其用于治疗各种神经学和/或精神疾病的方法。